ArticleFrontiers in oncology2026
Targeted plasma lipidomics in non-metastatic colorectal cancer, metastatic colorectal cancer, and healthy controls: an exploratory matched-triplet study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic lipid remodeling accompanies colorectal cancer (CRC), but whether circulating lipid alterations specifically distinguish metastatic from non-metastatic disease remains uncertain. Methods: This single-center prospective cross-sectional study enrolled newly diagnosed patients with non-metastatic CRC (nmCRC), metastatic CRC (mCRC), and healthy controls (HC) between September and December 2024. Two separate 1:1 nearest-neighbor propensity score matches used the same mCRC cohort as the anchor and histories of diabetes and hyperlipidemia as covariates. Matching was performed without replacement using a caliper of 0.2 on the raw propensity-score scale. Participant-level linkage generated 20 matched triplets. Fasting plasma samples underwent quantitative targeted lipidomic profiling. Primary lipid comparisons used matched-pair tests with comparison-specific Benjamini-Hochberg correction, and age- and sex-adjusted sensitivity analyses evaluated residual baseline imbalance. Results: Among 1,459 quantified lipids, 72 nominal differential lipids were identified in mCRC versus nmCRC, 186 in nmCRC versus HC, and 222 in mCRC versus HC using paired raw P<0.05. No lipid remained significant after false discovery rate correction in mCRC versus nmCRC, whereas 12 and 30 lipids remained significant in nmCRC versus HC and mCRC versus HC, respectively. After age and sex adjustment, the corresponding FDR-significant counts were 0, 10, and 9. Eight nominal candidates were shared across all three primary comparisons: BMP(14:0_20:0), BMP(14:0_20:1), Cer(d18:1/26:1), PC(18:2_18:2), PC(18:3_20:1), PC(18:3_20:4), PC(20:0_22:5), and PI(20:0_20:4). Conclusion: Plasma lipidomic differences were most reproducible between patients with CRC and healthy controls, particularly between mCRC and HC. Lipid differences between mCRC and nmCRC remained exploratory and hypothesis-generating. These findings indicate systemic lipid remodeling in CRC but do not establish metastasis-specific plasma biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.